search
Back to results

Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation (SleepTx-1)

Primary Purpose

Renal Disease, Sleep Disorders

Status
Completed
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
Bright Light Therapy
Wait-list intervention
Sponsored by
University of Basel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Renal Disease focused on measuring Sleep quality, Daytime Sleepiness

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • For phase 1: all renal transplant recipients transplanted at the University Hospital Basel, Bern and Zurich, speaking German and having an actual address on the follow-up list of the ambulatory center list.
  • Renal transplant recipients who have poor Sleep quality and /or daytime sleepiness (phase 1: Cross sectional survey study) and had a Sleep assessment (phase 2: Cross sectional diagnostic interview study)
  • Renal transplant recipients who participated in Phase 1 and 2 that were diagnosed with sleep wake dysregulation
  • Renal transplant recipients with signed written informed consent.

Exclusion Criteria:

  • RTx recipients, who participated in phase 2, will be excluded in the study if

    • they were diagnosed with sleep disorders as parasomnia, breathing disorders or movement disorders.
    • they were diagnosed with alcohol or substance abuse
    • they are blind or suffer from a severe vision impairment (cataract), which possibly limits the effect of the light intervention and patients taking photosensitive medications

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Other

    Arm Label

    Bright Light Therapy

    Wait-list intervention

    Arm Description

    Bright Light Therapy with 10000 lux beginning at day 21 until day 42

    Wait-list design Intervention. Bright Light Therapy with 10000 lux beginning at day 63 until day 84, when the 9 study weeks were over.

    Outcomes

    Primary Outcome Measures

    Bedtime
    The mean "bedtime" assessed by actimetry of each 3 week period (day 21, 42, 63 ) was used as outcome to be compared with the control group. Bedtime is expressed in time (hours and minutes)

    Secondary Outcome Measures

    Full Information

    First Posted
    December 8, 2010
    Last Updated
    January 29, 2014
    Sponsor
    University of Basel
    Collaborators
    University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, University Hospital, Zürich
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01256983
    Brief Title
    Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
    Acronym
    SleepTx-1
    Official Title
    Daily Light Intervention in Renal Transplant Recipients Having a Sleep-Wake Dysregulation
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    October 2010 (undefined)
    Primary Completion Date
    June 2013 (Actual)
    Study Completion Date
    July 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Basel
    Collaborators
    University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, University Hospital, Zürich

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Sleep-wake dysregulation is a disturbance in the roughly 24-hour cycle of the circadian rhythm. Well known disorders presenting a sleep-wake dysregulation are seasonal affective disorder, jet lag and shift work. These people experience a serious mood change when the seasons change. When the day-night rhythm is desynchronized, they have sleep disturbances, little energy, and often feel depressed. An established intervention to treat this disorder is bright light therapy. Light therapy is used for affective disorders for shift workers, jet lag symptomatology and for advancing or delaying desynchronized rhythms.Two proxy measures for sleep-wake dysregulation are sleep quality and daytime sleepiness. It is known from cross sectional studies that renal transplant (RTx) recipients have a prevalence between 30% to 62% of poor sleep quality measured by self report; a prevalence of impaired daytime functioning of 34% 12 and a prevalence of depressive symptomatology of 20% to 22%. Sleep-wake dysregulation in other chronically ill population are a risk factor for morbidity and mortality. RTx nurses in the follow-up care are in the frontline for recipient's symptoms respectively problems. The psychosocial variables that should be addressed, having an association with morbidity and mortality are sleep, daytime functioning, adherence to immunosuppressive medication, exercise, smoking and depressive symptomatology. In the following research project we will address the following gaps: the fact that nature of sleep disturbances in RTx recipients has never been assessed, that there is no prevalence available on sleep-wake dysregulation and that there is no data on bright light therapy intervention in RTx recipients. Hypothesis: Renal transplant recipients having a sleep wake disregulation will have an improved sleep quality and less daytime sleepiness after 21 days of light therapy.
    Detailed Description
    This research project has three phases: The first phase is a cross sectional survey including all patients transplanted in Basel, Bern and in Zurich speaking German and transplanted at least 6 months ago. Renal transplant recipients having poor sleep quality and / or daytime sleepiness as result of this first phase will be asked to participate in phase two. Phase two is an sleep assessment, resulting in a presumed sleep diagnosis. Renal transplant recipients having a sleep wake dysregulation, assessed in phase two, will be asked to participate in phase three. Phase three is a pilot randomized controlled trial to compare the sustained impact of bright light therapy on sleep-wake regulation.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Renal Disease, Sleep Disorders
    Keywords
    Sleep quality, Daytime Sleepiness

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Early Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    30 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Bright Light Therapy
    Arm Type
    Experimental
    Arm Description
    Bright Light Therapy with 10000 lux beginning at day 21 until day 42
    Arm Title
    Wait-list intervention
    Arm Type
    Other
    Arm Description
    Wait-list design Intervention. Bright Light Therapy with 10000 lux beginning at day 63 until day 84, when the 9 study weeks were over.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Bright Light Therapy
    Other Intervention Name(s)
    Philips Energy Light
    Intervention Description
    10000 Lux for 30 Minutes according to sleep wake rhythm
    Intervention Type
    Behavioral
    Intervention Name(s)
    Wait-list intervention
    Other Intervention Name(s)
    Philips Energy Light
    Intervention Description
    10000 Lux for 30 Minutes according to sleep wake rhythm
    Primary Outcome Measure Information:
    Title
    Bedtime
    Description
    The mean "bedtime" assessed by actimetry of each 3 week period (day 21, 42, 63 ) was used as outcome to be compared with the control group. Bedtime is expressed in time (hours and minutes)
    Time Frame
    Mean Bedtimes over 21 days for each period

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: For phase 1: all renal transplant recipients transplanted at the University Hospital Basel, Bern and Zurich, speaking German and having an actual address on the follow-up list of the ambulatory center list. Renal transplant recipients who have poor Sleep quality and /or daytime sleepiness (phase 1: Cross sectional survey study) and had a Sleep assessment (phase 2: Cross sectional diagnostic interview study) Renal transplant recipients who participated in Phase 1 and 2 that were diagnosed with sleep wake dysregulation Renal transplant recipients with signed written informed consent. Exclusion Criteria: RTx recipients, who participated in phase 2, will be excluded in the study if they were diagnosed with sleep disorders as parasomnia, breathing disorders or movement disorders. they were diagnosed with alcohol or substance abuse they are blind or suffer from a severe vision impairment (cataract), which possibly limits the effect of the light intervention and patients taking photosensitive medications
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Sabina De De Geest, PhD
    Organizational Affiliation
    Institute of Nursing Science
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    25182079
    Citation
    Burkhalter H, Wirz-Justice A, Denhaerynck K, Fehr T, Steiger J, Venzin RM, Cajochen C, Weaver TE, De Geest S. The effect of bright light therapy on sleep and circadian rhythms in renal transplant recipients: a pilot randomized, multicentre wait-list controlled trial. Transpl Int. 2015 Jan;28(1):59-70. doi: 10.1111/tri.12443. Epub 2014 Oct 2.
    Results Reference
    derived

    Learn more about this trial

    Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation

    We'll reach out to this number within 24 hrs